Skip main navigation

Investor Relations

Induced pluripotent stem cells are at the core of our company’s business

iPSCs have been heavily commercialized since their discovery in 2006 and can be used to generate any tissue type including cardiac muscle, nerves, liver, and blood.

iPSCs can be multiplied indefinitely and have a variety of applications including disease modeling, drug screening, and regenerative medicine.

Key Advantages of iPSCs

iPSCs have several advantages over medical technologies using other cell types.

  • iPSCs can differentiate (transform) into any other type of cell in the human body
  • iPSCs can multiply indefinitely, making them ideally suited for research and medicine
  • iPSCs are produced from the cells of the patient, so carry a reduced risk of transplant rejection
  • iPSCs avoid the ethical concerns of embryonic stem cells
ir-ips-cells-1

Applications of iPSCs

iPSCs can transform into any other cell and multiply easily granting them a wide range of applications.

Beyond their research capabilities, iPSCs have the potential for use in personalized medicine and donor-free regenerative treatments. Already, huge advances have been made in innovation in medical biotechnology as a result of the commercialization of iPSC technologies. Below, we have summarized the key products and services currently offered by REPROCELL and which customers they target.

ir-ips-cells-2

Research Reagents

At REPROCELL, we produce and sell reagents for iPSC research. These highly specialized reagents vary based on the type of iPSC, plus the methods used for multiplication and measurement. Products we offer researchers include culture fluids, dissociation solutions, preservation solutions, coatings, and antibodies.

Target customers:

  • Public research organizations e.g. universities
  • Private research organizations e.g. drug manufacturers
ir-ips-cells-3

Drug Discovery

We also produce iPSC-derived cells for use in drug discovery screening including patient-derived Alzheimer’s disease cells. These can be used by pharmaceutical companies to effectively evaluate the safety and efficacy of drug candidates. It is hoped that sophisticated in vitro models like these will largely replace animal testing in the future. 

Target customers:

  • Public research organizations e.g. universities
  • Private research organizations e.g. drug manufacturers
ir-ips-cells-4

Precision Medicine

In the future, iPSCs derived from a patient’s tissues could be used to assess treatment compatibility and identify the ideal dosing schedule for an individual patient.

Target customers: 

  • Individual patients
  • Public and private hospitals
ir-ips-cells-5

Regenerative Medicine

Until now, regenerative medicine has relied on a limited supply of tissues from human donors. As iPSCs can multiply indefinitely, they could be used to create an unlimited supply of somatic cells for transplantation, eliminating the need for tissue donors. At REPROCELL, we offer a GMP-grade iPSC master cell bank service that can be used to produce iPSCs for use in the clinical setting.

Target customers:

  • Patients
  • Hospitals

REPROCELL’s Growth Strategy

Across the globe, iPSC research is advancing. New technologies are broadening their applications in medical biotechnology. By responding to the market’s increasing demands with high-quality human iPSC-based products, we can expand and grow our business.

Our venture fund, Cell Innovation Partners, L.P., was established in partnership with the Shinsei Bank Group. It aims to acquire promising novel technologies, targeting ventures related to iPSCs or regenerative medicine and proactively investing globally.

ir-growth-strategy-1-1

Public Assistance and Development of Laws

As a growing industry, we are supported by the government in Japan.

As part of its growth plan, the Japanese administration has pledged 110 billion yen over 10 years to support medical research using iPSCs. It has also established a “Japanese National Institutes of Health”, based on the USA’s  NIH, and has revised the Pharmaceutical Affairs Law to approve medical technologies quicker.

REPROCELL’s headquarters is based in a special zone for iPSC Research 

We are based in Yokohama City, Kanagawa Prefecture, which is part of the Life Innovation in Keihin Coastal Areas “Comprehensive Special Zones for International Competitiveness Development”". This zone aims to increase international competitiveness by allowing global businesses to lead medicine and medical equipment production, helping related industries and SMEs prosper.

The legislation in Japan supports regenerative medicine

Two laws came into effect on November 25, 2014. These not only clarified the standards and processes for regenerative medicine products but also accelerated the approval process:

  1. The “Law on Guaranteeing Safety in Regenerative Medicine” or “Regenerative Medicine Law”
  2. The “Law on Guaranteeing Safety, Efficacy, and Quality in Medical Supplies and Equipment”, also called the “Medical Supplies and Equipment Law”
ir-competitive-edge-1

REPROCELL’s Competitive Edge

As a growing industry, we are supported by the government in Japan.

As part of its growth plan, the Japanese administration has pledged 110 billion yen over 10 years to support medical research using iPSCs. It has also established a “Japanese National Institutes of Health”, based on the USA’s  NIH, and has revised the Pharmaceutical Affairs Law to approve medical technologies quicker.

REPROCELL’s headquarters is based in a special zone for iPSC Research

We are based in Yokohama City, Kanagawa Prefecture, which is part of the Life Innovation in Keihin Coastal Areas “Comprehensive Special Zones for International Competitiveness Development”". This zone aims to increase international competitiveness by allowing global businesses to lead medicine and medical equipment production, helping related industries and SMEs prosper.

The legislation in Japan supports regenerative medicine

Two laws came into effect on November 25, 2014. These not only clarified the standards and processes for regenerative medicine products but also accelerated the approval process:

  1. The “Law on Guaranteeing Safety in Regenerative Medicine” or “Regenerative Medicine Law”
  2. The “Law on Guaranteeing Safety, Efficacy, and Quality in Medical Supplies and Equipment”, also called the “Medical Supplies and Equipment Law”
ir-competitive-edge-1

Safe Harbor Statement

Statements made on our website with respect to current plans, estimates, strategies, and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of REPROCELL Incorporated and REPROCELL Incorporated Group.

From time to time, oral or written forward-looking statements may also be included in other materials released to the public. These statements are based on management’s assumptions, judgments, and beliefs in light of the information currently available to it. REPROCELL Incorporated cautions you that a number of important risks and uncertainties could cause actual results to differ materially from those discussed in the forward-looking statements, and therefore you should not place undue reliance on them. You also should not rely on any obligation of REPROCELL Incorporated to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. REPROCELL Incorporated disclaims any such obligation. Risks and uncertainties that might affect REPROCELL Incorporated include, but are not limited to:

  1. The global economic environment which REPROCELL Incorporated or customer of REPROCELL Incorporated operates
  2. Fluctuation in foreign exchange rates
  3. Changes in the laws, regulations, and government policies in the jurisdictions where REPROCELL Incorporated operates
  4. Political and economic instability in the jurisdictions where REPROCELL Incorporated operates
  5. REPROCELL Incorporated’s ability to:
    1. Develop and introduce new products in a timely manner
    2. Recoup large-scale investments required for technology development and production capacity
    3. Devote sufficient resources to research and development
    4. Maintain product quality
    5. Forecast demands, manage timely procurement, and control inventories Risks related to catastrophic disasters or similar events

Therapeutic Pipeline

At REPROCELL, we are developing new strategies for treating rare central nervous system diseases.

We currently have two therapeutic products in our clinical pipeline, one made from Glial-restricted Progenitor Cells (GRPs) and another from Mesenchymal Stem Cells (MSCs).

Our GRP therapeutic is being developed in the United States, while the MSC being trailed in Taiwan, Japan, Korea, and the USA.

Products currently available in our therapeutic pipeline:

21JAN20 Glial Restricted Progenitor Cells GRPjpg

Q-cell GRP Cell Therapy

Our iPSC-GRPs are being developed in collaboration with Q Therapeutics Inc. in the United States. Preclinical iPSC-GRP research is currently taking place in our cGMP cell processing suite, located at the Life Innovation Center in Japan. So far, these therapeutics have demonstrated efficacy in the treatment of Amyotrophic Lateral Sclerosis and Transverse myelitis.

21JAN20 Mesnchymal Stem Cells MSC-3

Stemchymal MSC therapy

Stemchymal® is an allogenic cellular therapy derived from Mesenchymal stem cells. The therapeutic is being developed by Steminent Biotherapeutics, whom REPROCELL have an exclusive co-development and sale agreement with in Japan. Results from early stage clinical trials suggest that Stemchymal is safe for intravenous administration in humans. Phase II clinical trials are now underway to estimate efficacy of the treatment in patients with Spinocerebellar Ataxia.

Download our Corporate Profile Brochure (PDF)

Find out more about the history, philosophy, and business structure of REPROCELL.

Download our Corporate Capabilities Brochure (PDF)

Find out more about the services and products we offer to better translate your discoveries into therapies.